News

Wize Pharma‘s LO2A eye drops result in clinically meaningful improvements in dry eye signs and symptoms in people with Sjögren’s syndrome, topline results from an exploratory Phase 4 trial show. The treatment continued to demonstrate a good safety profile, and was found to be at least as…

Long-term use of hydroxychloroquine significantly lowers the risk of coronary artery disease, the most common form of heart disease, in people with Sjögren’s syndrome, a data study in Taiwan suggested. Its cardiovascular protective effects, in addition to a wider range of benefits, suggest the medication may control…

An immune regulatory molecule known as NEAT1 is produced at greater levels in the immune T-cells of people with primary Sjogren’s syndrome, and these levels seem to correlate with disease duration, a study has found. The findings suggest that NEAT1 may be used as a new…

Using the PI3K-delta inhibitor seletalisib as an add-on to standard treatment showed a trend toward easing disease activity and  dryness, and significantly lowered patient-reported fatigue in people with primary Sjögren’s syndrome (pSS), according to data from a Phase 2 trial. Findings from this proof-of-concept study (NCT02610543) —…

The National Institute of Arthritis and Musculoskeletal and Skin Diseases, a part of the National Institutes of Health, has awarded a $3.7 million grant to advance studies investigating which genes are associated with Sjögren’s syndrome. Led by Oklahoma Medical Research Foundation (OMRF) scientist Christopher Lessard, PhD,…

The use of sialendoscopy, an endoscopic tool to examine and treat the salivary glands, can be used to irrigate the major salivary glands with saline to increase salivation and lessen oral dryness in people with Sjögren’s syndrome, with benefits…

Interleukin-38, an immune signaling molecule known as IL-38, can reduce the inflammatory activity of a type of immune cells involved in primary Sjögren’s syndrome (pSS), and may be a therapeutic target for this condition, a new study suggests. The study, “Blockade of Th17 response by…

The arginase 1 protein appears to protect from dryness symptoms associated with Sjögren’s syndrome, potentially by lowering gland inflammation and increasing fluid secretion, a new study in mice indicates. The findings suggest this protein — a liver enzyme — as a possible therapeutic target for this condition. The study,…

Attention deficits may underlie the cognitive impairment that impacts a substantial portion of Sjögren’s syndrome patients with neurological symptoms, according to a new study. Such impairment is likely to affect other cognitive functions, as well as the ability to perform job-related tasks and engage in social activities, the researchers…

The tumor protein CA153 may be a valuable blood biomarker for the early diagnosis and treatment of interstitial lung disease (ILD) in people with primary Sjögren’s syndrome (pSS), a recent study found. The study, “Increases in tumor markers are associated with primary Sjögren’s syndrome-associated interstitial…